Engineered virus takes on Hard-to-Treat melanoma

NCT ID NCT03865212

Terminated Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a modified virus (VSV-IFNbetaTYRP1) in 12 patients with advanced melanoma that had spread or could not be removed by surgery. The virus was designed to infect and kill melanoma cells while also boosting the immune system's attack. The main goals were to find the safest dose and check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a modified virus (VSV-IFNbetaTYRP1) that carries extra genes to boost immune attack on melanoma cells
What this could lead to: If it works, this could point toward a new treatment option for advanced melanoma that has stopped responding to other therapies.
What could go wrong: This is a very early (Phase 1) trial with only 12 participants, so it is mainly about safety and dosing. The virus may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma malignant choroid melanoma melanoma metastatic melanoma mucosal melanoma ocular melanoma uveal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Engineered virus takes on Hard-to-Treat melanoma

Summary

What this could mean

Get notified about this study

Conditions

As listed by the trial registrant

Contacts and locations

Locations

More trials for these conditions